Genetic characterization and clinical course of IGHV3-21–expressing patients and of all patients within the previously described CLL cohort of 307 patients (study 1)3
| Patient characteristics . | IGHV3-21 . | Study 1* . |
|---|---|---|
| No. of patients | 63 | 307 |
| Median age, y | 59 | 52 |
| Age range, y | 39-79 | 30-77 |
| Male | 43 (68%) | 201 (65%) |
| Female | 20 (32%) | 106 (35%) |
| M IGHV | 30 (48%) | 143 (47%) |
| U IGHV | 33 (52%) | 164 (53%) |
| No. of patients with TTT and VH data available | 57 | 307 |
| M IGHV | 27 | 143 |
| Median time from diagnosis to first therapy, y | 5.7 | 9.2 |
| U IGHV | 30 | 164 |
| Median time from diagnosis to first therapy, y | 6.0 | 3.4 |
| No. of patients with TTT and sample collection data available | 57 | 307 |
| No. of nontreated patients | 25 (44%) | 223 (73%) |
| Median time from diagnosis to follow-up, y | 4.5 | 4.5 |
| Therapy after sample collection | 14 (24%) | 69 (31%) |
| Median time from diagnosis to first therapy, y | 3.0 | 4.0 |
| Therapy before sample collection | 18 (32%) | 84 (27%) |
| Median time from diagnosis to sample collection, y | 3.7 | 3.8 |
| Median time from diagnosis to first therapy, y | 1.5 | 1.8 |
| Patient characteristics . | IGHV3-21 . | Study 1* . |
|---|---|---|
| No. of patients | 63 | 307 |
| Median age, y | 59 | 52 |
| Age range, y | 39-79 | 30-77 |
| Male | 43 (68%) | 201 (65%) |
| Female | 20 (32%) | 106 (35%) |
| M IGHV | 30 (48%) | 143 (47%) |
| U IGHV | 33 (52%) | 164 (53%) |
| No. of patients with TTT and VH data available | 57 | 307 |
| M IGHV | 27 | 143 |
| Median time from diagnosis to first therapy, y | 5.7 | 9.2 |
| U IGHV | 30 | 164 |
| Median time from diagnosis to first therapy, y | 6.0 | 3.4 |
| No. of patients with TTT and sample collection data available | 57 | 307 |
| No. of nontreated patients | 25 (44%) | 223 (73%) |
| Median time from diagnosis to follow-up, y | 4.5 | 4.5 |
| Therapy after sample collection | 14 (24%) | 69 (31%) |
| Median time from diagnosis to first therapy, y | 3.0 | 4.0 |
| Therapy before sample collection | 18 (32%) | 84 (27%) |
| Median time from diagnosis to sample collection, y | 3.7 | 3.8 |
| Median time from diagnosis to first therapy, y | 1.5 | 1.8 |
Data are from Rassenti et al.3